<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="en">
	<id>https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Fosdenopterin</id>
	<title>Fosdenopterin - Revision history</title>
	<link rel="self" type="application/atom+xml" href="https://wikimd.org/index.php?action=history&amp;feed=atom&amp;title=Fosdenopterin"/>
	<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Fosdenopterin&amp;action=history"/>
	<updated>2026-04-26T21:35:56Z</updated>
	<subtitle>Revision history for this page on the wiki</subtitle>
	<generator>MediaWiki 1.44.2</generator>
	<entry>
		<id>https://wikimd.org/index.php?title=Fosdenopterin&amp;diff=6300616&amp;oldid=prev</id>
		<title>Prab: CSV import</title>
		<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Fosdenopterin&amp;diff=6300616&amp;oldid=prev"/>
		<updated>2025-02-16T16:28:54Z</updated>

		<summary type="html">&lt;p&gt;CSV import&lt;/p&gt;
&lt;a href=&quot;https://wikimd.org/index.php?title=Fosdenopterin&amp;amp;diff=6300616&amp;amp;oldid=2393350&quot;&gt;Show changes&lt;/a&gt;</summary>
		<author><name>Prab</name></author>
	</entry>
	<entry>
		<id>https://wikimd.org/index.php?title=Fosdenopterin&amp;diff=2393350&amp;oldid=prev</id>
		<title>Deepika vegiraju at 17:34, 13 July 2021</title>
		<link rel="alternate" type="text/html" href="https://wikimd.org/index.php?title=Fosdenopterin&amp;diff=2393350&amp;oldid=prev"/>
		<updated>2021-07-13T17:34:01Z</updated>

		<summary type="html">&lt;p&gt;&lt;/p&gt;
&lt;p&gt;&lt;b&gt;New page&lt;/b&gt;&lt;/p&gt;&lt;div&gt;== &amp;#039;&amp;#039;&amp;#039;What is Fosdenopterin?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* Fosdenopterin NULIBRY is &amp;#039;&amp;#039;&amp;#039;cyclic pyranopterin monophosphate&amp;#039;&amp;#039;&amp;#039; (cPMP) indicated to reduce the risk of mortality in patients with [[molybdenum cofactor deficiency]] (MoCD) Type A.&lt;br /&gt;
&lt;br /&gt;
&amp;lt;youtube&amp;gt;&lt;br /&gt;
title=&amp;#039;&amp;#039;&amp;#039;{{PAGENAME}}&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
movie_url=http://www.youtube.com/v/=NFq7jG9bNr4&lt;br /&gt;
embed_source_url=http://www.youtube.com/v/=NFq7jG9bNr4&lt;br /&gt;
&amp;amp;rel=1&lt;br /&gt;
wrap = yes&lt;br /&gt;
width=750&lt;br /&gt;
height=600&lt;br /&gt;
&amp;lt;/youtube&amp;gt;&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;What are the uses of this medicine?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* This medicine  is indicated to reduce the risk of mortality in patients with [[molybdenum cofactor deficiency]] (MoCD) Type A&amp;#039;&amp;#039;&amp;#039;.&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;How does this medicine work?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* Patients with MoCD Type A have mutations in the MOCS1 gene leading to deficient MOCS1A/B dependent synthesis of the intermediate substrate, cPMP. &lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Substrate replacement therapy with NULIBRY provides an exogenous source of cPMP, which is converted to molybdopterin&amp;#039;&amp;#039;&amp;#039;. &lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;Molybdopterin is then converted to molybdenum cofactor, which is needed for the activation of molybdenum-dependent enzymes&amp;#039;&amp;#039;&amp;#039;, including sulfite oxidase (SOX), an enzyme that reduces levels of neurotoxic sulfites.&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;Who Should Not Use this medicine ?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* This medicine have no usage limitation&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;What drug interactions can this medicine cause?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;Is this medicine FDA approved?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* It was approved for use in the United States in 2021.&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;How should this medicine be used?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
* Start NULIBRY if known or presumed MoCD Type A. Promptly discontinue if MoCD Type A is not confirmed by genetic testing.&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Recommended Dosage and Administration in Patients Less Than One Year of Age (by gestational age)&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
&lt;br /&gt;
The recommended dosage regimen of NULIBRY in patients less than one year of age (by gestational age) is based on actual body weight as shown below&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Preterm Neonates(Gestational Age Less than 37 Weeks):&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
* Initial Dosage-0.4 mg/kg once daily&lt;br /&gt;
* Month 1 -0.7 mg/kg once daily&lt;br /&gt;
* Month 3 -0.9 mg/kg once daily&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Term Neonates (Gestational Age 37 weeks and Above)&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
* Initial Dosage-0.55 mg/kg once daily&lt;br /&gt;
* Month 1-0.75 mg/kg once daily&lt;br /&gt;
* Month 3-0.9 mg/kg once daily&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Recommended Dosage and Administration in Patients One Year of Age or Older&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
* For patients one year of age or older, the recommended dosage of NULIBRY is 0.9 mg/kg (based on actual body weight) administered as an intravenous infusion once daily.&lt;br /&gt;
&lt;br /&gt;
&amp;#039;&amp;#039;&amp;#039;Administration&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
* NULIBRY is intended for administration by a healthcare provider. If deemed appropriate by a healthcare provider, NULIBRY may be administered at home by the patient&amp;#039;s caregiver. &lt;br /&gt;
* If NULIBRY can be administered by a caregiver/patient, advise them to read the detailed instructions on the preparation, administration, storage, and disposal of NULIBRY for caregivers .&lt;br /&gt;
* NULIBRY is for intravenous infusion only. &lt;br /&gt;
* Administer with non-DEHP tubing with a 0.2 micron filter. &lt;br /&gt;
* Do not mix NULIBRY with other drugs (note NULIBRY is reconstituted with Sterile Water for Injection, USP). &lt;br /&gt;
* Do not administer as an infusion with other drugs.&lt;br /&gt;
* NULIBRY is given through an infusion pump at a rate of 1.5 mL per minute.&lt;br /&gt;
* Dose volumes below 2 mL may require syringe administration through slow intravenous push.&lt;br /&gt;
* Administration of NULIBRY must be completed within 4 hours of reconstitution &lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;What are the  dosage forms and brand names of this medicine?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
This medicine is available in fallowing doasage form:&lt;br /&gt;
* &amp;#039;&amp;#039;&amp;#039;As injection: &amp;#039;&amp;#039;&amp;#039;9.5 mg of fosdenopterin as a lyophilized powder or cake in a single-dose vial for reconstitution.&lt;br /&gt;
&lt;br /&gt;
This medicine is available in fallowing brand namesː&lt;br /&gt;
*&amp;#039;&amp;#039;&amp;#039;NULIBRY&amp;#039;&amp;#039;&amp;#039;&lt;br /&gt;
&lt;br /&gt;
==&amp;#039;&amp;#039;&amp;#039;What side effects can this medication cause?&amp;#039;&amp;#039;&amp;#039;==&lt;br /&gt;
&lt;br /&gt;
The most common side effects of this medicine include:&lt;br /&gt;
* [[pyrexia]], viral infection&lt;br /&gt;
* pneumonia&lt;br /&gt;
* [[otitis media]]&lt;br /&gt;
* vomiting&lt;br /&gt;
* cough/sneezing&lt;br /&gt;
* viral upper respiratory infection&lt;br /&gt;
* [[gastroenteritis]]&lt;br /&gt;
* [[bacteremia]]&lt;br /&gt;
* diarrhea&lt;br /&gt;
&lt;br /&gt;
==&amp;#039;&amp;#039;&amp;#039; What special precautions should I follow?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* Limit or avoid your child&amp;#039;s exposure or time in sunlight and artificial ultraviolet (UV) light, such as [[UVA]] or [[UVB]] [[phototherapy]].&lt;br /&gt;
* Your child should wear clothing, a hat, and sunglasses that protect against sun exposure.&lt;br /&gt;
* If your child is 6 months of age or older apply a broad spectrum sunscreen with high sun protection factor.&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;What to do in case of emergency/overdose?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* {{overdose}}&lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;Can this medicine be used in pregnancy?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* There are no available data on NULIBRY use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. &lt;br /&gt;
&lt;br /&gt;
==&amp;#039;&amp;#039;&amp;#039;Can this medicine be used in children?&amp;#039;&amp;#039;&amp;#039;==&lt;br /&gt;
&lt;br /&gt;
* Safety and effectiveness of NULIBRY for the treatment of MoCD Type A have been established in pediatric patients starting from birth. &lt;br /&gt;
&lt;br /&gt;
== &amp;#039;&amp;#039;&amp;#039;What should I know about storage and disposal of this medication?&amp;#039;&amp;#039;&amp;#039; ==&lt;br /&gt;
&lt;br /&gt;
* Store NULIBRY frozen between -25°C and -10°C (-13°F and 14°F). &lt;br /&gt;
* Store the vial in its original carton to protect from light. &lt;br /&gt;
* For storage recommendations for the reconstituted solution.&lt;br /&gt;
&lt;br /&gt;
{{Portal bar | Medicine}}&lt;br /&gt;
&lt;br /&gt;
[[Category:Breakthrough therapy]]&lt;br /&gt;
[[Category:Orphan drugs]]&lt;br /&gt;
[[Category:Organophosphates]]&lt;br /&gt;
{{coststubd}}&lt;br /&gt;
{{orphan_drugs}}&lt;/div&gt;</summary>
		<author><name>Deepika vegiraju</name></author>
	</entry>
</feed>